MetaCap

Agenus (AGEN) vs AgomAb Therapeutics NV (AGMB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Agenus is the larger company by market cap ($270.1 million vs $268.4 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AGEN+103.06%AGMB-62.80%
+253%+87%-78%
Feb 6, 20261 yearNov 20, 2026
AGEN+103.06%AGMB-62.80%
+203%+64%-75%
Feb 2, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AGEN versus AGMB key metrics
MetricAGENAGMB
Share price$5.97$5.45
Market cap$270.12M$268.40M
1-day change-2.77%-3.02%
YTD return+90.13%—
1-year return+41.47%—
5-year return-90.58%—
P/E ratio (TTM)25.96—
EPS (TTM)$0.23$-2.08
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$114.20M—
Revenue growth (YoY)+10.37%—
Net income (latest FY)$-3.08M—
Gross margin99.11%—
Operating margin-17.66%—
Net margin-2.70%—
52-week high$10.31$17.82
52-week low$2.71$5.39
Distance from 52-week high-42.10%-69.42%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+352.26%+591.19%
Average volume905.17K208.99K
Shares outstanding45.25M49.25M
Employees8162
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Agenus

AGEN stock →

Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 81 employees

About AgomAb Therapeutics NV

AGMB stock →

AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 62 employees

AGEN vs AGMB FAQ

Which is bigger, Agenus or AgomAb Therapeutics NV?

Agenus (AGEN) is larger, with a market capitalization of $270.12M compared with $268.40M for AgomAb Therapeutics NV (AGMB).

Are Agenus and AgomAb Therapeutics NV in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons